[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335988-105":59,"doc-detail-335988-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-flrt3-unc5b-checkpoint-pathway-inhibits-t-cellbased-cancer-immunotherapies","The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies","","Cancers can escape tumor immunity by exploiting coinhibitory receptors on T cells, reducing response to existing immune checkpoint inhibitor therapies in many patients. The study proposes that cancer cells mimic noncanonical early-development axon guidance mechanisms to evade T cell immunity. Gain-of-function genetic screens identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that suppresses T cell activity via UNC5B. FLRT3 in human cancers supports growth and impairs CAR-T and BiTE killing and infiltration in humanized models; an FLRT3 monoclonal antibody reversing these effects supports targeting axon-guidance checkpoints for immunotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-flrt3-unc5b-checkpoint-pathway-inhibits-t-cellbased-cancer-immunotherapies/335988/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-flrt3-unc5b-checkpoint-pathway-inhibits-t-cellbased-cancer-immunotherapies/335988.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What immune-evasion mechanism does the study propose for cancer cells?","Question",{"text":113,"@type":114},"The study proposes that cancer cells mimic noncanonical early-development axon guidance pathways to evade T cell immunity by using checkpoint-like ligand-receptor pairs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was FLRT3 identified in the study?",{"text":118,"@type":114},"Using gain-of-function genetic screens, the researchers profiled axon guidance proteins on human T cells and their ligands, identifying fibronectin leucine-rich transmembrane protein 3 (FLRT3) as an inhibitory ligand.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the functional pathway through which FLRT3 inhibits T cells?",{"text":122,"@type":114},"FLRT3 inhibits T cells through UNC5B, an axon guidance receptor up-regulated on activated human T cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335988,1790073279,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","IMMUNOLOGY  \nThe FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies  \nKushal Prajapati1, Chuan Yan2,3†‡, Qiqi Yang2,3†, Steven Arbitman1†, Daniel P. Fitzgerald1, Sasan Sharee1, Jahangheer Shaik1, Jason Bosiacki1, Kayla Myers1, Ana Paucarmayta1, Dorothy M. Johnson1, Thomas O’Neill1, Subhadip Kundu1, Zachary Cusumano1, Solomon Langermann1, David M. Langenau2,3, Shashank Patel1, Dallas B. Flies1*  \nCancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligandsand identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.  \ncopyright © 2024 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nCancer immunotherapy, one of the key scientific breakthroughs against cancer, was pioneered by targeting T cell coinhibitory immune checkpoint inhibitors (ICIs), with U.S. Food and Drug Administration– approved therapies including anti-CTLA-4 (ipilimumab) and anti– PD-1 (nivolumab) for melanoma in 2011 and 2014, respectively (1) . Since then additional ICIs have been identified and developed for the clinic (2–5) . Despite outstanding efficacy in several cancers, most patients remain nonresponsive to current ICI immunotherapies (6) . This suggests that many additional and unknown immune inhibitory mechanisms may be active or adaptively activated in cancer, leading to evasion ofT cell immunity, which remain to be fully explored.  \nAxon guidance molecules (AGMs) are a family of proteins that play a pivotal role in neuronal development by providing molecular cues to guide the migration of developing neurons (7) . Numerous studies have shown that the role of AGMs such as semaphorins, ephrins, slits, and netrins go beyond neuronal development to cell migration, adhesion, and apoptosis (8) as well as tumorigenesis, angiogenesis, and metastasis in cancers (9–15). Recently, the ability of AGMsto regulate inflammation and immune response in and outside of the neuronal system has received attention in the field (16, 17) . Here, we present compelling evidence that AGM ligand-receptor pairs mimic coinhibitory pathways that can disrupt antitumor T cell immunity.  \nRESULTS  \nDiscovery screening was performed to identify axon guidance coinhibitory mimics  \nAGMs were identified through queries made in publication, gene, transcript, and protein databases including PubMed, National Center  \n1nextcure inc., Beltsville, Md 20705, USA. 2Molecular Pathology and cancer center, Massachusetts General hospital Research institute, charlestown, MA 02129, USA. 3harvard Stem cell institute, cambridge, MA 02139, USA.  \n*[corresponding author. email: fliesd@nextcure.com](corresponding author. email: fliesd@nextcure.com)  \n†Present address: institute of Molecular and cell Biology, Agency for Science, technology, and Research (A*StAR), Singapore 138673, Singapore.  \n‡these authors contributed equally to this work.  \nfor Biot","cbCaiaSwpXGV6G5f","https://ap.wps.com/l/cbCaiaSwpXGV6G5f","pdf",6527716,15,"English","# Introduction\n# Results\n## Discovery screening to identify axon guidance coinhibitory mimics","[{\"question\":\"What immune-evasion mechanism does the study propose for cancer cells?\",\"answer\":\"The study proposes that cancer cells mimic noncanonical early-development axon guidance pathways to evade T cell immunity by using checkpoint-like ligand-receptor pairs.\"},{\"question\":\"How was FLRT3 identified in the study?\",\"answer\":\"Using gain-of-function genetic screens, the researchers profiled axon guidance proteins on human T cells and their ligands, identifying fibronectin leucine-rich transmembrane protein 3 (FLRT3) as an inhibitory ligand.\"},{\"question\":\"What is the functional pathway through which FLRT3 inhibits T cells?\",\"answer\":\"FLRT3 inhibits T cells through UNC5B, an axon guidance receptor up-regulated on activated human T cells.\"}]","The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies | PDF",1790013064,38]